Universal Digital Health

Lecture 3.2.8: FDA Digital Health & CE Mark Pathways

The lecture walks developers through the regulatory maze for software‑based medical devices, comparing the U.S. FDA framework with the European CE‑mark pathway. It defines "software as a medical device" (SaMD), outlines the FDA’s three‑tier risk classification, and explains how each tier dictates the appropriate market‑entry route. Key insights include the three U.S. pathways—510(k) clearance for predicate‑based tools, the de novo route for novel low‑to‑moderate risk products, and the PMA for high‑risk devices—along with their typical timelines (3‑6 months, 6‑12 months, and 12‑24 months respectively). The EU’s MDR focuses heavily on documentation, quality‑system compliance, and notified‑body audits, with Rule 11 classifying SaMD into low, medium, and high risk. Both regions now demand a Software Bill of Materials (SBOM) and rigorous post‑market surveillance. Illustrative examples such as an AI‑powered skin‑cancer detection app (high‑risk Tier 3) and a medication‑reminder app (low‑risk Tier 1) highlight how intended‑use language can shift a product’s classification. The 2026 TEMA pilot is introduced as a rolling‑review mechanism to accelerate high‑impact AI tools, while the speaker stresses the importance of aligning technical files to satisfy both FDA and MDR requirements. For innovators, harmonizing documentation to meet the stricter MDR standards can cover roughly 80% of FDA expectations, streamlining global market entry, reducing time‑to‑value, and protecting investment. Mastering regulatory strategy is thus as critical as building the predictive model itself.